Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aadi Bioscience, Inc. (AADI)

7.25   -0.04 (-0.55%) 03-24 16:00
Open: 7.22 Pre. Close: 7.29
High: 7.29 Low: 7.09
Volume: 116,879 Market Cap: 177(M)

Technical analysis

as of: 2023-03-24 4:23:42 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 11.65     One year: 13.8
Support: Support1: 7    Support2: 5.82
Resistance: Resistance1: 9.97    Resistance2: 11.82
Pivot: 7.92
Moving Average: MA(5): 7.4     MA(20): 8.57
MA(100): 11.85     MA(250): 13.08
MACD: MACD(12,26): -1.1     Signal(9): -1.1
Stochastic oscillator: %K(14,3): 7.9     %D(3): 10.2
RSI: RSI(14): 26
52-week: High: 18.46  Low: 7
Average Vol(K): 3-Month: 124 (K)  10-Days: 160 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AADI ] has closed above bottom band by 20.3%. Bollinger Bands are 35.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.3 - 7.34 7.34 - 7.37
Low: 7.01 - 7.04 7.04 - 7.08
Close: 7.19 - 7.25 7.25 - 7.3

Company Description

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Headline News

Thu, 23 Mar 2023
100+ Active Companies working to Develop 100+ Pipeline ... - Digital Journal

Tue, 21 Mar 2023
Aadi Bioscience (AADI) to Release Earnings on Tuesday - MarketBeat

Thu, 16 Mar 2023
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates - Nasdaq

Thu, 16 Mar 2023
Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update - MarketBeat

Fri, 03 Mar 2023
Aadi Bioscience Announces Leadership Transition - PR Newswire

Tue, 28 Feb 2023
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 ... - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 24 (M)
Shares Float 16 (M)
% Held by Insiders 11.6 (%)
% Held by Institutions 63.4 (%)
Shares Short 1,080 (K)
Shares Short P.Month 1,180 (K)

Stock Financials

EPS -8.9
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.23
Profit Margin (%) 0
Operating Margin (%) -540.9
Return on Assets (ttm) -20.5
Return on Equity (ttm) -39.2
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.77
Sales Per Share 0.45
EBITDA (p.s.) -2.43
Qtrly Earnings Growth 0
Operating Cash Flow -51 (M)
Levered Free Cash Flow -30 (M)

Stock Valuations

PE Ratio -0.82
PEG Ratio 0
Price to Book value 1
Price to Sales 16.09
Price to Cash Flow -3.49

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.